Gestational Diabetes Mellitus Does Not Change the Pharmacokinetics and Transplacental Distribution of Fluoxetine and Norfluoxetine Enantiomers
<b>Background/Objectives</b>: Fluoxetine (FLX) is the inhibitor of serotonin reuptake most prescribed in pregnant women with depression. This study evaluates the influence of gestational diabetes mellitus (GDM) on the enantioselective pharmacokinetics and transplacental distribution of F...
Saved in:
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-12-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/17/1/35 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832587706547306496 |
---|---|
author | Daniela Miarelli Carvalho Glauco Henrique Balthazar Nardotto Gabriela Campos de Oliveira Filgueira Geraldo Duarte Ricardo Carvalho Cavalli Vera Lucia Lanchote Elaine Christine Dantas Moisés |
author_facet | Daniela Miarelli Carvalho Glauco Henrique Balthazar Nardotto Gabriela Campos de Oliveira Filgueira Geraldo Duarte Ricardo Carvalho Cavalli Vera Lucia Lanchote Elaine Christine Dantas Moisés |
author_sort | Daniela Miarelli Carvalho |
collection | DOAJ |
description | <b>Background/Objectives</b>: Fluoxetine (FLX) is the inhibitor of serotonin reuptake most prescribed in pregnant women with depression. This study evaluates the influence of gestational diabetes mellitus (GDM) on the enantioselective pharmacokinetics and transplacental distribution of FLX and its metabolite norfluoxetine (norFLX). <b>Methods</b>: Ten pregnant women diagnosed with GDM (GDM group) were investigated in the third trimester of gestation after they achieved good glycemic control. They received a single oral dose of 20 mg FLX, and blood samples were collected from 0 to 672 h. On the day of delivery, after another single oral dose of 20 mg FLX, blood samples of maternal vein, umbilical vessels and intervillous space were collected at birth. The pharmacokinetics parameters obtained for pregnant women diagnosed with GDM were compared with a group of healthy pregnant women (n = 9) previously investigated using Kruskal–Wallis’s rank-sum test with the Dunn–Bonferroni post hoc test. <b>Results</b>: The area under the plasma over time curve (AUC<sub>0–∞</sub>) were 197.93 and 109.62 ng∙h/mL for FLX and 600.39 and 960.83 ng∙h/mL for norFLX, respectively, for their R-(+)- and S-(-)- enantiomers. The umbilical vein/maternal vein ratio for FLX and norFLX enantiomers was nearly 0.3, inferring low placental transfer. The umbilical artery/umbilical vein ratios were nearly 0.7 for both FLX and norFLX enantiomers, indicating absence or small fetal metabolism. <b>Conclusions</b>: The GDM did not alter the pharmacokinetics of FLX and norFLX enantiomers in patients with good glycemic control evaluated in the third trimester of gestation. |
format | Article |
id | doaj-art-440430ceece249b694d48a55e38aaafc |
institution | Kabale University |
issn | 1999-4923 |
language | English |
publishDate | 2024-12-01 |
publisher | MDPI AG |
record_format | Article |
series | Pharmaceutics |
spelling | doaj-art-440430ceece249b694d48a55e38aaafc2025-01-24T13:45:39ZengMDPI AGPharmaceutics1999-49232024-12-011713510.3390/pharmaceutics17010035Gestational Diabetes Mellitus Does Not Change the Pharmacokinetics and Transplacental Distribution of Fluoxetine and Norfluoxetine EnantiomersDaniela Miarelli Carvalho0Glauco Henrique Balthazar Nardotto1Gabriela Campos de Oliveira Filgueira2Geraldo Duarte3Ricardo Carvalho Cavalli4Vera Lucia Lanchote5Elaine Christine Dantas Moisés6Department of Obstetrics and Gynecology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, BrazilDepartment of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-903, SP, BrazilDepartment of Obstetrics and Gynecology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, BrazilDepartment of Obstetrics and Gynecology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, BrazilDepartment of Obstetrics and Gynecology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, BrazilDepartment of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto 14040-903, SP, BrazilDepartment of Obstetrics and Gynecology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, Brazil<b>Background/Objectives</b>: Fluoxetine (FLX) is the inhibitor of serotonin reuptake most prescribed in pregnant women with depression. This study evaluates the influence of gestational diabetes mellitus (GDM) on the enantioselective pharmacokinetics and transplacental distribution of FLX and its metabolite norfluoxetine (norFLX). <b>Methods</b>: Ten pregnant women diagnosed with GDM (GDM group) were investigated in the third trimester of gestation after they achieved good glycemic control. They received a single oral dose of 20 mg FLX, and blood samples were collected from 0 to 672 h. On the day of delivery, after another single oral dose of 20 mg FLX, blood samples of maternal vein, umbilical vessels and intervillous space were collected at birth. The pharmacokinetics parameters obtained for pregnant women diagnosed with GDM were compared with a group of healthy pregnant women (n = 9) previously investigated using Kruskal–Wallis’s rank-sum test with the Dunn–Bonferroni post hoc test. <b>Results</b>: The area under the plasma over time curve (AUC<sub>0–∞</sub>) were 197.93 and 109.62 ng∙h/mL for FLX and 600.39 and 960.83 ng∙h/mL for norFLX, respectively, for their R-(+)- and S-(-)- enantiomers. The umbilical vein/maternal vein ratio for FLX and norFLX enantiomers was nearly 0.3, inferring low placental transfer. The umbilical artery/umbilical vein ratios were nearly 0.7 for both FLX and norFLX enantiomers, indicating absence or small fetal metabolism. <b>Conclusions</b>: The GDM did not alter the pharmacokinetics of FLX and norFLX enantiomers in patients with good glycemic control evaluated in the third trimester of gestation.https://www.mdpi.com/1999-4923/17/1/35fluoxetinenorfluoxetineenantiomerspharmacokineticspregnancyplacental transfer |
spellingShingle | Daniela Miarelli Carvalho Glauco Henrique Balthazar Nardotto Gabriela Campos de Oliveira Filgueira Geraldo Duarte Ricardo Carvalho Cavalli Vera Lucia Lanchote Elaine Christine Dantas Moisés Gestational Diabetes Mellitus Does Not Change the Pharmacokinetics and Transplacental Distribution of Fluoxetine and Norfluoxetine Enantiomers Pharmaceutics fluoxetine norfluoxetine enantiomers pharmacokinetics pregnancy placental transfer |
title | Gestational Diabetes Mellitus Does Not Change the Pharmacokinetics and Transplacental Distribution of Fluoxetine and Norfluoxetine Enantiomers |
title_full | Gestational Diabetes Mellitus Does Not Change the Pharmacokinetics and Transplacental Distribution of Fluoxetine and Norfluoxetine Enantiomers |
title_fullStr | Gestational Diabetes Mellitus Does Not Change the Pharmacokinetics and Transplacental Distribution of Fluoxetine and Norfluoxetine Enantiomers |
title_full_unstemmed | Gestational Diabetes Mellitus Does Not Change the Pharmacokinetics and Transplacental Distribution of Fluoxetine and Norfluoxetine Enantiomers |
title_short | Gestational Diabetes Mellitus Does Not Change the Pharmacokinetics and Transplacental Distribution of Fluoxetine and Norfluoxetine Enantiomers |
title_sort | gestational diabetes mellitus does not change the pharmacokinetics and transplacental distribution of fluoxetine and norfluoxetine enantiomers |
topic | fluoxetine norfluoxetine enantiomers pharmacokinetics pregnancy placental transfer |
url | https://www.mdpi.com/1999-4923/17/1/35 |
work_keys_str_mv | AT danielamiarellicarvalho gestationaldiabetesmellitusdoesnotchangethepharmacokineticsandtransplacentaldistributionoffluoxetineandnorfluoxetineenantiomers AT glaucohenriquebalthazarnardotto gestationaldiabetesmellitusdoesnotchangethepharmacokineticsandtransplacentaldistributionoffluoxetineandnorfluoxetineenantiomers AT gabrielacamposdeoliveirafilgueira gestationaldiabetesmellitusdoesnotchangethepharmacokineticsandtransplacentaldistributionoffluoxetineandnorfluoxetineenantiomers AT geraldoduarte gestationaldiabetesmellitusdoesnotchangethepharmacokineticsandtransplacentaldistributionoffluoxetineandnorfluoxetineenantiomers AT ricardocarvalhocavalli gestationaldiabetesmellitusdoesnotchangethepharmacokineticsandtransplacentaldistributionoffluoxetineandnorfluoxetineenantiomers AT veralucialanchote gestationaldiabetesmellitusdoesnotchangethepharmacokineticsandtransplacentaldistributionoffluoxetineandnorfluoxetineenantiomers AT elainechristinedantasmoises gestationaldiabetesmellitusdoesnotchangethepharmacokineticsandtransplacentaldistributionoffluoxetineandnorfluoxetineenantiomers |